Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9686943 | 0.93 | POLB (0.55) | L3MBTL1POLBHTTSMN1; SMN2NPSR1 | |
| SCHEMBL9684769 | 0.87 | L3MBTL1 (0.50) | L3MBTL1POLBHTTSMN1; SMN2NPSR1 | |
| SCHEMBL2876824 | 0.86 | L3MBTL1 (0.60) | L3MBTL1POLBHTTSMN1; SMN2NPSR1 | |
| SCHEMBL2876829 | 0.85 | L3MBTL1 (0.58) | L3MBTL1POLBHTTSMN1; SMN2NPSR1 | |
| SCHEMBL31568278 | 0.83 | L3MBTL1 (0.54) | L3MBTL1POLBHTTSMN1; SMN2NPSR1 | |
| SCHEMBL11888397 | 0.83 | GAA (0.64) | L3MBTL1HTTSMN1; SMN2MAPTGAA | |
| SCHEMBL13034123 | 0.83 | MAOB (0.59) | L3MBTL1POLBHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13811589 | 0.83 | L3MBTL1 (0.54) | L3MBTL1POLBHTTSMN1; SMN2NPSR1 | |
| SCHEMBL336642 | 0.81 | ALDH1A1 (0.51) | L3MBTL1POLBHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6236731 | 0.80 | MAOB (0.57) | L3MBTL1POLBHTTSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| CN-101056640-A | Aerosol formulation for the inhalation of beta-agonists | BOEHRINGER INGELHEIM INT (DE) | 2007-10-17 | — | — | CN | disclosed |
| CN-101035540-A | Pharmaceutical combinations containing benzoxazine for treating respiratory diseases | BOEHRINGER INGELHEIM INT (DE) | 2007-09-12 | — | — | CN | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| CN-1946406-A | Benzoxazines for treating respiratory diseases | BOEHRINGER INGELHEIM INT (DE) | 2007-04-11 | — | — | CN | disclosed |
| CN-1713914-A | Novel drug for treating chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-28 | — | — | CN | disclosed |
| US-5078838-A | By electrochemical anodic oxidation of benzyl derivatives in the presence of an aliphatic alcohol | BASF AKTIENGESELLSCHAFT (DE) | 1992-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | L3MBTL1 1548/4885POLB 3099/4885HTT 1110/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | L3MBTL1 1548/4885POLB 3099/4885HTT 1110/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | L3MBTL1 1548/4885POLB 3099/4885HTT 1110/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | L3MBTL1 1548/4885POLB 3099/4885HTT 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.